Literature DB >> 22526618

Intravitreal bevacizumab for iatrogenic choroidal neovascularization due to laser photocoagulation in central serous chorioretinopathy.

Yoko Nomura1, Ryo Obata, Yasuo Yanagi.   

Abstract

BACKGROUND: Choroidal neovascularization (CNV) is well recognized as a complication of laser photocoagulation for central serous chorioretinopathy (CSC). However, little is known about its management. PATIENTS: Two patients who developed iatrogenic CNV after laser photocoagulation for CSC. OBSERVATIONS: A single intravitreal bevacizumab (IVB) injection was given in both cases. The best-corrected visual acuity (BCVA) of 1 of the patients improved from 0.3 to 0.5 on the following day and to 1.2 three months after the IVB, and the BCVA of the other patient improved from 0.5 to 1.0 two weeks after the IVB. In both cases, the CNV became inactive 1 month after IVB on fluorescein angiography and remained stable for over 1 year.
CONCLUSION: IVB was beneficial for iatrogenic CNV that developed after laser photocoagulation for CSC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22526618     DOI: 10.1007/s10384-012-0138-3

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


  17 in total

1.  Restoration of outer segments of foveal photoreceptors after resolution of central serous chorioretinopathy.

Authors:  Yumiko Ojima; Akitaka Tsujikawa; Kenji Yamashiro; Sotaro Ooto; Hiroshi Tamura; Nagahisa Yoshimura
Journal:  Jpn J Ophthalmol       Date:  2010-02-12       Impact factor: 2.447

2.  Photocoagulation treatment of idiopathic central serous choroidopathy.

Authors:  J D Gass
Journal:  Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol       Date:  1977 May-Jun

3.  Intravitreal bevacizumab for choroidal neovascularization secondary to laser photocoagulation for central serous chorioretinopathy.

Authors:  Joseph Pikkel; Shimon Rumelt
Journal:  Eur J Ophthalmol       Date:  2012 May-Jun       Impact factor: 2.597

4.  Direct, indirect, and sham laser photocoagulation in the management of central serous chorioretinopathy.

Authors:  D M Robertson; D Ilstrup
Journal:  Am J Ophthalmol       Date:  1983-04       Impact factor: 5.258

5.  Experimental central serous chorioretinopathy. III: ultrastructural findings.

Authors:  H Yoshioka; Y Katsume
Journal:  Jpn J Ophthalmol       Date:  1982       Impact factor: 2.447

6.  Quantitative Analysis of Indocyanine Green Angiographic Image in Central Serous Chorioretinopathy.

Authors:  Y Nishiyama; K Mori; K Murayama; S Yoneya
Journal:  Jpn J Ophthalmol       Date:  2001-01       Impact factor: 2.447

7.  Polypoidal choroidal vasculopathy masquerading as central serous chorioretinopathy.

Authors:  L A Yannuzzi; K B Freund; M Goldbaum; B Scassellati-Sforzolini; D R Guyer; R F Spaide; D Maberley; D W Wong; J S Slakter; J A Sorenson; Y L Fisher; D A Orlock
Journal:  Ophthalmology       Date:  2000-04       Impact factor: 12.079

8.  Argon laser photocoagulation treatment in central serous chorioretinopathy.

Authors:  D M Robertson
Journal:  Ophthalmology       Date:  1986-07       Impact factor: 12.079

9.  Photodynamic therapy for iatrogenic CNV due to laser photocoagulation in central serous chorioretinopathy.

Authors:  Mehmet Cakir; Osman Cekiç; Omer F Yilmaz
Journal:  Ophthalmic Surg Lasers Imaging       Date:  2009 Jul-Aug

Review 10.  Central serous chorioretinopathy.

Authors:  Maria Wang; Inger Christine Munch; Pascal W Hasler; Christian Prünte; Michael Larsen
Journal:  Acta Ophthalmol       Date:  2007-07-28       Impact factor: 3.761

View more
  5 in total

1.  Half-dose photodynamic therapy for chronic central serous chorioretinopathy evaluated by focal macular electroretinograms.

Authors:  Kazuhiro Oiwa; Keiko Kataoka; Ruka Maruko; Shinji Ueno; Yasuki Ito; Hiroko Terasaki
Journal:  Jpn J Ophthalmol       Date:  2017-02-02       Impact factor: 2.447

2.  Long-Term Outcome of Half-Dose Verteporfin Photodynamic Therapy for the Treatment of Central Serous Chorioretinopathy (An American Ophthalmological Society Thesis).

Authors:  Timothy Y Y Lai; Raymond L M Wong; Wai-Man Chan
Journal:  Trans Am Ophthalmol Soc       Date:  2015

3.  Clinical characteristics of responders to intravitreal bevacizumab in central serous chorioretinopathy patients.

Authors:  G A Kim; T H Rim; S C Lee; S H Byeon; H J Koh; S S Kim; C S Lee
Journal:  Eye (Lond)       Date:  2015-05-08       Impact factor: 3.775

4.  Combined choroidal neovascularization and hypopituitarism in a patient with homozygous mutation in methylenetetrahydrofolate reductase gene.

Authors:  Aydogan Aydogdu; Cem Haymana; Kamil Baskoy; Ali H Durukan; Gokhan Ozgur; Omer Azal
Journal:  J Res Med Sci       Date:  2014-01       Impact factor: 1.852

5.  Laser-Induced Choroidal Neovascularizations: Clinical Study of 3 Cases.

Authors:  Wipada Laovirojjanakul; Thuss Sanguansak; Yosanan Yospaiboon; Supat Sinawat; Suthasinee Sinawat
Journal:  Case Rep Ophthalmol       Date:  2017-08-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.